NCT06060977Phase 1/2Completed
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants
A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants With 50% or Greater Scalp Hair Loss
In the register
The register attaches this trial to Olevaprubart (IMG-007) (ImageneBio), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 1/2
- Sponsor
- Inmagene LLC
- Participants (registry)
- 29
- Start
- September 2023
- Primary completion
- January 2025
- Study completion
- January 2025
- Last registry update
- February 2026
- Countries
- United States, Canada
Conditions studied: Alopecia Areata (AA)
Interventions: IMG-007
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.